首页> 外文OA文献 >Combination of InnoSEAL plus TR band compared with TR band alone for radial artery outcomes in patients undergoing transradial coronary intervention (InnoSEAL-II): an open-label randomised controlled trial (protocol)
【2h】

Combination of InnoSEAL plus TR band compared with TR band alone for radial artery outcomes in patients undergoing transradial coronary intervention (InnoSEAL-II): an open-label randomised controlled trial (protocol)

机译:Innoseal Plus Tr带的组合与单独的TR带,用于接受颅冠介入的患者的桡动脉结果(InnoSeal-II):开放标签随机对照试验(协议)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction About 2%–30% of cardiac catheterisation procedures get complicated by radial artery occlusion (RAO). Ensuring patent haemostasis appears to be an important factor in reducing RAO. Currently employed method is a radial compression device (RCD) such as transradial band (TRB) that take hours to achieve haemostasis and cause discomfort to the patients. Haemostatic pads offer an alternative to RCD with reduced time to achieve haemostasis. Our trial aims to determine the non-inferiority of the catecholamine chitosan-based pad (InnoSEAL haemostatic pad) used in conjunction with TRB (InnoSEAL +TRB) when compared with the TRB alone in reducing composite adverse access site outcomes.Methods and analysis It will be an open-label, parallel, randomised controlled trial on 714 adult patients (325 in each arm) undergoing coronary procedure using transradial approach at a cardiac health facility over 7 months duration. InnoSEAL patch along with TRB will be used to control bleeding in intervention arm and TRB alone in control arm, which is the standard practice. Study primary outcomes include RAO and haematoma; secondary outcomes are compression time, patient discomfort, time to discharge and ease of use of the intervention technique by the healthcare staff. χ2 test will be used to compare the categorical outcomes between two arms and student’s t-test for continuous outcomes. A p value of <0.05 will be considered significant.Ethics and dissemination Ethical approval for the study has been obtained from the Institutional Review Board of Tabba Heart Institute number IORG0007863. Findings will be disseminated through seminars and scientific publications.Trial registration number NCT04380883; Pre-results.
机译:引言约2%-30%的心脏导管诱导程序通过桡动脉闭塞(RAO)复杂。确保专利血肿似乎是减少RAO的一个重要因素。目前所采用的方法是径向压缩装置(RCD),如颅底带(TRB),需要几小时才能实现血肿,并且对患者产生不适。止血垫提供RCD的替代方案,减少了实现止血的时间。我们的试验旨在确定与TRB(InnoSeal + TRB)结合使用的CateCholamine壳聚糖的垫(Innoseal Haemostatic Pad)的非自效性,当单独的TRB相比,单独减少复合不良接入站点结果。方法和分析它将在714名成年患者(每只臂325患者中,是在3个月持续时间超过7个月的心脏病保健机构的冠状动物程序的开放标签,平行,随机对照试验。 Innoseal补丁以及TRB将用于控制干预臂和TRB的流血,仅在控制臂中,这是标准做法。研究主要结果包括Rao和血肿;二次结果是压缩时间,患者的不适,时间来放电和易于使用医疗保健工作人员。 χ2试验将用于比较两个武器和学生T检验之间的分类结果,以进行连续结果。 P值为<0.05将被认为是显着的。从Tabba心脏学院IORG0007863的机构审查委员会获得了研究的言论和传播伦理批准。调查结果将通过研讨会和科学出版物传播。注册号NCT04380883;预先结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号